© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
March 31st 2021
Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.
Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.
April 7th 2021
A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.
Experts in oncology provide their insights on the use of companion diagnostics in the treatment of solid tumors.
April 14th 2021
Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.
Dr Lori Wirth describes the importance and implications of testing for NRTK fusions in patients with solid tumors.
April 21st 2021
Benjamin Levy, MD, reviews the available treatment options for patients whose tumors harbor NRTK fusions.
Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.
April 28th 2021
Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.
Expert oncologists discuss RET-driven therapy for select solid tumors.
May 5th 2021
Lori Wirth, MD, reviews the phase 1/2 LIBRETTO-001 trial.
Dr Jyoti Patel presents data from the ARROW clinical trial.
May 12th 2021
Dr Mark Socinski describes the design and findings of the CRESTONE trial.
Experts in oncology discuss future directions in biomarker-driven therapy.